Held by 8 specialist biotech funds
High Convergence# Signal Note: RA Capital Initiates $407.5M Position in Sionna Therapeutics RA Capital's substantial entry into SION signals confidence in Sionna's pipeline, likely centered on its lead program targeting fibrotic diseases through selective autotaxin inhibition—a validated mechanism in IPF and other progressive fibroses.
AI analyst context — unlock full analysis
## Baker Bros. Initiates $16.5B Position in Sionna Therapeutics (SION) **Note: The reported position value of ~$16.5B on 400K shares appears to be a data error — likely a misformatted 13F filing or pricing anomaly — and should be verified against actual market cap before acting on this signal.** That said, Baker Bros. initiating *any* new position in SION is notable given their concentrated, high-conviction biotech strategy. Sionna is developing SNN-1535, a potentiator/corrector combination therapy targeting cystic fibrosis (CF) — directly challenging Vertex's CFTR franchise dominance — and Baker's entry likely reflects conviction in upcoming clinical data readouts that could validate a differentiated mechanism and open a multi-billion-dollar CF market to competition.
+ 6 more positions with dollar amounts and AI context
Unlock All — 7-Day Free Trial